Valeo Financial Advisors LLC Has $156,000 Stock Position in R1 RCM Inc. (NASDAQ:RCM)

Valeo Financial Advisors LLC reduced its stake in shares of R1 RCM Inc. (NASDAQ:RCM) by 75.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,993 shares of the healthcare provider’s stock after selling 33,155 shares during the quarter. Valeo Financial Advisors LLC’s holdings in R1 RCM were worth $156,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Advisors Asset Management Inc. bought a new stake in shares of R1 RCM in the 1st quarter worth approximately $27,000. GAMMA Investing LLC lifted its position in R1 RCM by 41.3% in the third quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider’s stock worth $37,000 after purchasing an additional 759 shares during the period. ANTIPODES PARTNERS Ltd acquired a new stake in R1 RCM during the second quarter worth $86,000. QRG Capital Management Inc. bought a new stake in R1 RCM in the 1st quarter valued at $132,000. Finally, CIBC Asset Management Inc acquired a new position in shares of R1 RCM in the 2nd quarter valued at $149,000. 61.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Stephens lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Leerink Partners downgraded R1 RCM from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $17.00 to $14.30 in a report on Thursday, August 1st. Morgan Stanley cut R1 RCM from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $19.00 price target on shares of R1 RCM in a research note on Friday, June 28th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $18.00 price objective on shares of R1 RCM in a research note on Tuesday, July 2nd. Thirteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $15.41.

R1 RCM Price Performance

RCM opened at $14.23 on Wednesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.84 and a quick ratio of 1.84. The stock has a market capitalization of $5.99 billion, a P/E ratio of -177.88 and a beta of 0.85. The company’s 50 day simple moving average is $14.11 and its 200-day simple moving average is $13.09. R1 RCM Inc. has a one year low of $8.87 and a one year high of $15.12.

R1 RCM (NASDAQ:RCM) last announced its quarterly earnings data on Wednesday, August 7th. The healthcare provider reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The firm had revenue of $627.90 million for the quarter, compared to analyst estimates of $633.10 million. R1 RCM had a negative return on equity of 1.44% and a negative net margin of 1.68%. The firm’s revenue was up 12.0% compared to the same quarter last year. Sell-side analysts anticipate that R1 RCM Inc. will post -0.24 earnings per share for the current fiscal year.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.